Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Panel Narrowly Recommends Medtronic Spine Treatment After Tough Scrutiny

This article was originally published in The Gray Sheet

Executive Summary

An FDA advisory panel cast a mixed vote on July 27 in support of Medtronic's Amplify rhBMP-2 Matrix spinal treatment, reflecting disagreement about safety and the reliability of some clinical data

You may also be interested in...



Medtronic’s Amplify Spine Product Not Approvable, FDA Says

Medtronic received a non-approvable letter from FDA for its Amplify rhBMP-2 Matrix spinal treatment, the company disclosed in a March 9 regulatory filing.

Medtronic’s Amplify Spine Product Not Approvable, FDA Says

Medtronic received a non-approvable letter from FDA for its Amplify rhBMP-2 Matrix spinal treatment, the company disclosed in a March 9 regulatory filing.

Medicare Panel Gives Wish List For Bone Morphogenetic Protein Research

Cross-industry cooperation may be needed to develop more effective bone morphogenetic proteins to promote bone growth and fusion, according to a Medicare advisory panel

Related Content

Topics

UsernamePublicRestriction

Register

MT029203

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel